Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS

References

• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS 100 years after the discovery of Cryptococcus neoformans. Gun Microbiol Rev 1995; 8: 515–548.
   PubMed Web of Science ®Google Scholar
• Cahn P, Cuatz D, Guelfand L, Kaufman S, Perez H. Crypto-coccal meningitis is a frequent first AIDS-defining illness with high rates of relapse in Argentina. In: 35th Interscience Confer-ence on Antimicrobial and Chemotherapy. San Francisco. 1995. Washington DC: American Society for Microbiology. 1995: Abstract 1–98.
   Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126–131.
   PubMed Web of Science ®Google Scholar
• Van der Horst Ch, Saag MS, Gretchen AC, et al. Treatment of cryptococcal meningitis associated with immunodeficiency syn-drome. N Engl J Med 1997; 337: 15–21. 0 2000 1SHAM, Medical Mycology, 38, 201-207
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Refer-ence Method for Broth Dilution Antifungal Susceptibility Test-ing of Yeasts. Approved Standard M27-A. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
   Google Scholar
• Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489–495.
   Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro—in vivo correla-tion data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–247.
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Ibrahim AS, Fu Y, Shafiq C, Edwards Jr JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 30: 2881–2886.
   PubMed Web of Science ®Google Scholar
• Odds FC, De Backer T, Dams G, Vranckx L, Woestenborghs F. Oxygen as limiting nutrient for growth of Cryptococcus neoformans. J Clin Microbiol 1995; 33: 995–997.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Revankar SG, et al. Compara-tive evaluation of National Committee for Clinical Laboratory Standards broth macrodilution screening method for testing fluconazole susceptibility of Cryptococcus neoformans. J Clin Microbiol 1998; 36: 1330–1332.
   PubMed Web of Science ®Google Scholar
• Davey KG, Johnson EM, Holmes AD, Szekely A, Warnock DW. In vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J Antimicrob Chemother 1998; 42: 217–220.
   Google Scholar
• Davey KG, Holmes AD, Johnson EM, Szekely A, Warnock DW. Comparative evaluation of FUNGITEST and broth mi-crodilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Mi-crobiol 1998; 36: 926–930.
   Google Scholar
• Witt MD, Lewis RJ, Larsen RA, et al. Identification of pa-tients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifun-gal susceptibility testing. Clin Infect Dis 1996; 22: 322–328.
   PubMed Web of Science ®Google Scholar
• Johnson CC. In vitro testing: correlation between bactericidal susceptibility, body fluids levels and effectiveness of antibacte-rial therapy. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore: The Williams & Wilkins Co, 1996: 813–834.
   Google Scholar
• Kreger-van Rij NJW. The Yeasts, a Taxonomic Study, 3rd edn. Amsterdam: Elsevier Science, 1984.
   Google Scholar
• Odds FC, Vranckx L, Woestenborghs F. Antifungal suscepti-bility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 1995; 39: 2051–2060.
   Google Scholar
• Perfect JR, Cox GM, Dodge RK, Schell. WA. In vitro and in vivo efficacies of the azole 5CH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910-1913.
   Google Scholar
• Walsh TJ, Melcher GP, Rinaldi MG, et al. Trichasporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616–1622.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Berg J, Nguyen. MH. Emergence of fluconazole resistance in C. neoformans. The hidden danger of primary fluconazole prophylaxis in HIV-infected patients, In: Program and abstracts of the IDSA 35th Annual Meeting, Toronto, Canada, 1997; Boston: Infectious Diseases Society of America, 1997: 528.
   Google Scholar
• Casadevall A, Spitzer EC, Webb D, Rinaldi M. Susceptibility of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993; 37: 1383–1386.
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Taylor M, Conan AJ, Baldwin BC, Powderly WC. Resistance to amphotericin B associated with sterol AS' 7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett 1994; 122: 39–42.
   PubMed Web of Science ®Google Scholar
• Powderly WG, Keath El, Sokol-Anderson M, Kitt D, Russell Little J, Kobayashi G. Amphotericin B-resistant Crypt °coccus neoformans in a patient with AIDS. Infect Dis Clin Pract 1992; 1: 314–316.
   Google Scholar
• Piancastelli Franzot S, Soares Hadman J. Effect of ampho-tericin B on the lipids of five different strains of Cryptococcus neoformans. Mycopathologia 1994; 28: 85–88.
   Google Scholar
• Currie B, Sanati H, Ibrahim AS, Edwards JE, Casadevall A, Ghannoum MA. Sterol composition and susceptibilities to am-photericin B of environmental Cryptococcus neoformans iso-lates are changed by murine passage. Antimicrob Agents Chemother 1995; 39: 1934–1937.
   PubMedGoogle Scholar